Nebenwirkungen · Leqembi
LEQEMBI 100 mg/mL concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-150417 · Präparat HOS-100312
In Study 301, ARIA-E was observed in 9% (67/757) of patients on lecanemab compared with 1% (10/764) of patients on placebo. The majority of ARIA-E was asymptomatic, with symptomatic ARIA-E reported in 2% (12/757) of patients on lecanemab and no patients on placebo. When present, reported symptoms associated with ARIA-E included headache (50%, 6/12), confusion (17%, 2/12), dizziness (8%, 1/12) and nausea (8%, 1/12). Focal neurologic deficits (8%, 1/12) also occurred.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-08-05T11:45:00Z · SHA-256 b5b97a1240d6c003d96cd8b3294bef8b3b5d33af33f6be54cfceee548b126f2d · Passage bf74a8c028ae34beb9cd8f229079bc6bad13bfef59467a7f54247da9f58a0def · Zeichen 5031–5501 im Abschnitt